CRC tumor cells with PI3KCA mutations or PTEN loss have been shown to be associated with increased PDL-1 expression, a key immune checkpoint molecule, thereby conferring resistance to anti-PD1 therapy [137]. This evidence concerns the gene CD274 and colorectal carcinoma.